Georgina V. Long, MD, MSc, discussed the long-term follow-up data for the combination of adjuvant dabrafenib and trametinib ...

In December 2024, the first patient was treated in a global randomized Phase 2 clinical trial (IMCODE004; NCT06534983) evaluating autogene cevumeran in combination with nivolumab compared to nivolumab ...

where it dominates the immunotherapy market – as well as newer indications like kidney cancer and adjuvant treatment of melanoma. The six-week regimen is helping to consolidate its lead in the ...

The study enrolled 64 patients with treatment-naïve metastatic melanoma between March 2017 and July 2019. Participants ...

SAN FRANCISCO -- Post-surgical adjuvant nivolumab (Opdivo) improved survival outcomes in muscle-invasive bladder cancer (MIBC), regardless of the use of neoadjuvant chemotherapy, according to ...

Those who had residual disease after neoadjuvant nivolumab proceeded to surgery and adjuvant therapy. Pathologic or clinical complete response rate served as the primary endpoint. Secondary ...

The DEPEND study evaluated nivolumab as a neoadjuvant immunotherapy in human papilloma virus-negative locoregionally advanced head and neck cancer. Nivolumab is already an FDA approved treatment ...

“As we enter 2025, we continue enrolling patients in our three Phase 3 melanoma trials, pursuing additional opportunities in our PRAME franchise, and developing the next generation of ...

Readers are advised this story contains graphic images. She was diagnosed with nodular melanoma, an aggressive form of cancer that can grow and spread quickly. "From that day forward, it's been a ...